Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial

Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The study record for the Phase 2 investigation of apremilast added to dupilumab for atopic dermatitis is available, with study details and results information. The record also includes linked study documents, including the protocol and statistical analysis plan.
    Difference
    46%
    Check dated 2026-11-08T13:09:46.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-11-01T13:21:29.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH website transition and says “Super Intelligence” will be used in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T13:16:53.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The site footer's revision identifier advances from v3.7.1 to v3.7.2. The study page remains a 403 Forbidden error page.
    Difference
    0.2%
    Check dated 2026-10-18T13:15:25.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:17:13.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed when attempting to view the NCT04306965 record, replacing the study details and navigation. This indicates access restrictions or a broken link preventing the display of the record content.
    Difference
    18%
    Check dated 2026-09-20T10:34:20.000Z thumbnail image

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.